Patents by Inventor Rajesh Babulal Gandhi

Rajesh Babulal Gandhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
    Publication number: 20230277672
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous(SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: November 3, 2022
    Publication date: September 7, 2023
    Inventors: Manisha P Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
    Publication number: 20200230242
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 23, 2020
    Inventors: Manisha P. DESAI, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Stable subcutaneous protein formulations and uses thereof
    Patent number: 10265401
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Manisha P Desai, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF
    Publication number: 20180360965
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 20, 2018
    Inventors: Manisha P. Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF
    Publication number: 20160263223
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Inventors: Manisha P DESAI, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Stable subcutaneous protein formulations and uses thereof
    Patent number: 9309316
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha D. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Stable protein formulations
    Patent number: 8476239
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 2, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha M. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
    Patent number: 8252821
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: August 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Bioavailable Capsule Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound
    Publication number: 20100260837
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Application
    Filed: April 12, 2010
    Publication date: October 14, 2010
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Stable Protein Formulations
    Publication number: 20100166774
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: December 19, 2006
    Publication date: July 1, 2010
    Inventors: Manisha M. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar